Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

40.0%

6 terminated/withdrawn out of 15 trials

Success Rate

50.0%

-36.6% vs industry average

Late-Stage Pipeline

33%

5 trials in Phase 3/4

Results Transparency

50%

3 of 6 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 2

6(42.9%)

Phase 3

4(28.6%)

Phase 1

3(21.4%)

Phase 4

1(7.1%)

14Total

Phase 2(6)

Phase 3(4)

Phase 1(3)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (15)

Showing 15 of 15 trials

NCT04620239Phase 3Active Not Recruiting

ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study

Role: lead

NCT03133650Phase 1Active Not Recruiting

A Trial of a New Type of Photodynamic Therapy (VTP) in the Treatment of Patients With Cancer of the Esophagus Who Have Trouble Swallowing

Role: collaborator

NCT03315754Phase 2Active Not Recruiting

Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer.

Role: lead

NCT00946881Phase 1Completed

Safety and Tolerability Study Using WST11 In Patients With Localized Prostate Cancer

Role: lead

NCT03849365Phase 4Terminated

Study of Erectile Dysfunction, Urinary Incontinence and Related QoL After TOOKAD® VTP for Low Risk Prostate Cancer

Role: lead

NCT04017325Completed

European Randomised Study of TOOKAD® Soluble for Prostate Cancer vs Active Surveillance. Post Study Follow-up

Role: lead

NCT04225299Phase 3Withdrawn

Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate Cancer

Role: lead

NCT01310894Phase 3Completed

Efficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance.

Role: lead

NCT01021956Phase 2Terminated

Safety and Preliminary Efficacy Study of WST11 (Stakel®)-Mediated VTP Therapy in Subjects With CNV Associated With AMD

Role: lead

NCT01573156Phase 1Terminated

Vascular Targeted Photodynamic Therapy T1a Renal Tumours

Role: collaborator

NCT01875393Phase 3Completed

Efficacy,Safety and Quality of Life After TOOKAD® Soluble VTP for Localized Prostate Cancer

Role: lead

NCT00707356Phase 2Completed

Study of WST11 in Patients With Localized Prostate Cancer

Role: lead

NCT00975039Phase 2Terminated

Study Using WST11 in Patients With Non-Resectable or Inoperable Cholangiocarcinoma

Role: lead

NCT00974662Phase 2Terminated

Study Using WST11 in Patients With Obstructing Endobronchial Non-Small Cell Lung Cancer

Role: lead

NCT00975429Phase 2Completed

Study Using WST11 in Patients With Localized Prostate Cancer

Role: lead

All 15 trials loaded